Lilly (LLY) Stock Down as FDA Delays Decision on Donanemab

Eli Lilly and Company’s (LLY) stock declined 2.3% on Friday after it announced that an FDA decision on its regulatory filing for an important pipeline candidate, donanemab, its anti-amyloid beta antibody for early symptomatic Alzheimer's disease, will be delayed.Donanemab biologics license application (BLA) was based on data from the TRAILBLAZER-ALZ 2 confirmatory phase III study. Lilly said an FDA advisory committee will be convened to discuss data from the TRAILBLAZER-ALZ 2 study to get more information a ...